$5.80
1.36% yesterday
NYSE, Aug 01, 10:00 pm CET
ISIN
US29384C1080
Symbol
TRDA

Entrada Therapeutics Stock price

$5.80
-1.31 18.42% 1M
-7.53 56.49% 6M
-11.49 66.45% YTD
-10.16 63.66% 1Y
-5.78 49.91% 3Y
-18.15 75.78% 5Y
-18.15 75.78% 10Y
-18.15 75.78% 20Y
NYSE, Closing price Fri, Aug 01 2025
-0.08 1.36%
ISIN
US29384C1080
Symbol
TRDA
Industry

Key metrics

Basic
Market capitalization
$220.1m
Enterprise Value
$-162.4m
Net debt
positive
Cash
$382.5m
Shares outstanding
37.9m
Valuation (TTM | estimate)
P/E
9.7 | negative
P/S
1.3 | 4.6
EV/Sales
negative | negative
EV/FCF
2.8
P/B
0.5
Financial Health
Equity Ratio
81.5%
Return on Equity
15.3%
ROCE
0.9%
ROIC
4.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$172.2m | $47.7m
EBITDA
$7.9m | $-137.8m
EBIT
$4.1m | $-148.4m
Net Income
$24.8m | $-122.4m
Free Cash Flow
$-58.0m
Growth (TTM | estimate)
Revenue
5.7% | -77.4%
EBITDA
-70.8% | -371.3%
EBIT
-82.7% | -415.6%
Net Income
5.5% | -286.5%
Free Cash Flow
38.2%
Margin (TTM | estimate)
Gross
-
EBITDA
4.6% | -288.7%
EBIT
2.4%
Net
14.4% | -256.5%
Free Cash Flow
-33.7%
More
EPS
$0.6
FCF per Share
$-1.5
Short interest
6.3%
Employees
168
Rev per Employee
$1.3m
Show more

Is Entrada Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Entrada Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

Buy
90%
Hold
10%

Financial data from Entrada Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
172 172
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 39 39
17% 17%
23%
- Research and Development Expense 129 129
22% 22%
75%
7.89 7.89
71% 71%
5%
- Depreciation and Amortization 3.79 3.79
16% 16%
2%
EBIT (Operating Income) EBIT 4.11 4.11
83% 83%
2%
Net Profit 25 25
6% 6%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Entrada Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entrada Therapeutics Stock News

Neutral
GlobeNewsWire
2 months ago
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Neutral
GlobeNewsWire
2 months ago
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Comm...
Neutral
GlobeNewsWire
2 months ago
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries und...
More Entrada Therapeutics News

Company Profile

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Dipal Doshi
Employees 168
Founded 2016
Website www.entradatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today